GlassScriptPhysician profile
Caleb David Morton
NPI 1881191708
$3,535.72
in general payments reported to CMS, 2019-2025
28 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $542 · 2023: $612 · 2024: $1,079 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.55 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $459.80 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $378.90 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $320.76 | 2021-2025 | |
| Dexcom, INC. | $301.19 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $206.45 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $195.27 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $178.53 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $96.10 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.10 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.99 | 2025 | Caplyta |
| Amgen INC. | $46.51 | 2022-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $46.26 | 2021 | |
| Sunovion Pharmaceuticals INC. | $40.99 | 2022 | |
| Azurity Pharmaceuticals, INC. | $37.98 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $33.03 | 2023-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $32.29 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $29.30 | 2025 | Rexulti |
| Shield Therapeutics INC | $24.16 | 2025 | |
| Astellas Pharma US INC | $23.16 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $21.37 | 2025 | Austedo Xr |
| Biosense Webster, INC. | $18.02 | 2025 | Carto 3 |
| Inspire Medical Systems, INC. | $16.69 | 2025 | Inspire |
| Corcept Therapeutics | $16.15 | 2024 | Korlym |
| Viiv Healthcare Company | $15.86 | 2025 | Apretude |
| Xeris Pharmaceuticals, INC. | $15.66 | 2025 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.